Morningside Venture Investments Ltd purchased $5.0M of APMD

Apnimed's sleep apnea pill AD109 has a February 28, 2027, FDA decision date. The drug showed a 44.1% reduction in breathing interruptions in trials, but the FDA questioned its clinical meaningfulness. Apnimed (APMD) relies on this single product, and its future hinges on FDA approval.

Apnimed, Inc. (Nasdaq: APMD) priced and closed an upsized Nasdaq IPO raising $220.8M in gross proceeds. It sold 13.8M shares at $16.00 each, including 1.8M from the underwriters’ overallotment option. Shares began trading July 31, 2026. The company develops AD109 for obstructive sleep apnea, with two Phase 3 trials completed and an NDA PDUFA goal date of Feb. 28, 2027.

Apnimed raised $192M in its Nasdaq IPO, pricing 12M shares at $16 and debuting as APMD at $25, up 56% on the day. The company’s lead candidate Oxnimbi (formerly AD109) is under FDA review for obstructive sleep apnea. Apnimed submitted a new drug application in April; the FDA accepted it with a Feb. 28, 2027 decision date.

Apnimed Inc. (Nasdaq: APMD) jumped 56% in its Nasdaq debut after pricing an enlarged $192M IPO. It sold 12M shares at $14-$16, closing at $25. The company reported $84.8M revenue and $67.7M net income for the quarter ended March 31. It is developing Oxnimbi for obstructive sleep apnea, with an FDA marketing request filed in April.

CAMBRIDGE, Mass., July 30, 2026 /PRNewswire/ -- Apnimed, Inc. ("Apnimed"), a late stage clinical pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced the pricing of its upsized initial public offering of 12,000,000 shares of its common stock at a price to the public of $16.00 per share.

S. Korea’s KOSPI surges over 16% as Samsung, SK Hynix rebound after Wall St rally Apnimed, Inc., a Cambridge, Massachusetts-based clinical-stage pharmaceutical company, has priced its initial public offering of 12 million shares of common stock at $16.00 per share, according to a press release issued July 30, 2026. The company expects to raise $192 million in gross proceeds before deducting underwriting discounts, commissions, and offering expenses.